A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Megadott ok: Sponsor Decision: The trial has been withdrawn with no plans to continue development.
Key facts
- Where
- Houston, Seattle és Tampa, Egyesült ÁllamokSee the 3 sites
- Phase
- 2. fázis
Where in Egyesült Államok
- Clinical Trial NetworkHouston, Egyesült ÁllamokNo longer taking part
- Swedish Medical Center-501 E Hampden AveSeattle, Egyesült ÁllamokNo longer taking part
- University of South FloridaTampa, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Loxo Oncology, Inc.
- Trial code
- NCT06104683EU 2022-502376-24-00
- Record updated
- 2024. március 27.
- Original description
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.Read full original descriptionShow less
A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis
The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.
Inclusion: Participants must have been diagnosed with relapsing MS; Participants must have one of the following; at least 1 documented relapse within the previous year, or; at least 2 documented relapse within the previous 2 years, or; at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.
Exclusion: Had a relapse of MS within 30 days prior to randomization; Have a history of another clinically significant neurological disease; Have had a diagnosis of primary progressive MS.